Skip to main content

Table 1 DOX-induced LV dysfunction and remodeling after 12 weeks chronic treatment is greater in sGCα1-/- than WT mice:

From: Cardiac soluble guanylate cyclase protects against the cardiac dysfunction induced by chronic doxorubicin treatment in mice

Echocardiography

WT + saline (n=7)

sGCα1-/- + saline (n=6)

WT + DOX (n=12)

sGCα1-/- + DOX (n=11)

LVIDS (mm)

1.3±0.1

1.3±0.0

1.7±0.1†

2.0±0.1†*

LVIDD (mm)

3.0±0.0

3.0±0.0

3.2±0.1†

3.3±0.0†

FS (%)

57±1

57±1

48±2†

40±1†*

HR (bpm)

531±13

505±18

428±17†

426±18†

Hemodynamic measurements

WT + saline (n=6)

sGCα1-/- + saline (n=5)

WT + DOX (n=12)

sGCα1-/- + DOX (n=9)

ESV (μl)

19±1

19±1

26±3†

37±3†*

EDV (μl)

43±2

41±2

51±2†

58±2†*

EF (%)

60±2

58±3

55±4

42±3†*

dP/dtmax (mmHg/s)

13,499±1,433

11,995±601

13,503±678

10,386±875*

dP/dtmin (mmHg/s)

-12,053±1,809

-11,420±950

-13,531±846

-10,943±940¶

Tau (ms)

5.1±0.1

4.9±0.2

5.6±0.2†

6.3±0.3†¶

PRSW

83±9

84±6

70±9

49±7†¶

Ees (mmHg/μl)

6.3±1.2

7.3±1.4

4.0±0.8†

2.3±0.3†¶

EDPVR (mmHg/μl)

0.21±0.03

0.18±0.02

0.16±0.02

0.19±0.02

HR (bpm)

576±8

614±12

528±9†

530±14†*

  1. LVIDS indicates left ventricular internal diameter at end-systole; LVIDD, left ventricular internal diameter at end-diastole; FS, fractional shortening; HR, heart rate; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; dP/dtmax and dP/dtmin, maximum and minimum of the first derivative of LV pressure over time; Tau, time constant for isovolumic relaxation; PRSW, pre-load recruitable stroke work; Ees, end-systolic elastance; and EDPVR, end-diastolic pressure volume relationship. Values are presented as mean±SEM.
  2. P<0.05 vs. saline,
  3. * P<0.05 vs. WT + DOX, and
  4. P≤0.10 vs. WT + DOX.